A Phase II Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist
Status: Active_not_recruiting
Location: See all (18) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This Phase II study is a randomized, parallel group, double blinded, placebo-controlled, multicenter to evaluate the efficacy, safety, and tolerability of AZD6234 in adults with overweight or obesity and type 2 diabetes on stable GLP-1 RA therapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: t
View:
• Be 18 to 75 years old at the time of signing the informed consent.
• Diagnosed with type 2 diabetes ≥ 180 days before screening.
• HbA1c value at screening of ≥ 6.0% (42 mmol/mol) and ≤ 10% (86 mmol/mol).
• On a stable maintenance dose of an injectable GLP-1 RA.
• At Screening, have a BMI ≥ 27 kg/m2
Locations
United States
Alabama
Research Site
Birmingham
Research Site
Mobile
Florida
Research Site
Doral
Research Site
Jacksonville
Research Site
Miami
Research Site
Miami
Research Site
Winter Park
Georgia
Research Site
Canton
Research Site
Fayetteville
Illinois
Research Site
Chicago
Research Site
Oak Brook
Kansas
Research Site
Newton
Kentucky
Research Site
Lexington
Missouri
Research Site
Kansas City
Nevada
Research Site
Las Vegas
Oklahoma
Research Site
Norman
Tennessee
Research Site
Knoxville
Texas
Research Site
San Antonio
Time Frame
Start Date: 2025-03-12
Completion Date: 2026-05-27
Participants
Target number of participants: 69
Treatments
Experimental: AZD6234
Weekly SC injections of AZD6234
Placebo_comparator: Placebo for AZD6234
Weekly SC injections of matching placebo
Related Therapeutic Areas
Sponsors
Leads: AstraZeneca